Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Sight Sciences (SGHT) Stock Price & Analysis

107 Followers

SGHT Stock Chart & Stats

$9.68$0.26(2.76%)
At close: 4:00 PM EST
$6$7$8$9Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$8.99 - $10.06
52-Week Range
$3.38 - $10.06
Previous Close
$9.42
Volume
N/A
Average Volume (3M)
344.48K
Market Cap
$518.93M
Enterprise Value
$257.64M
Total Cash (Recent Filing)
$77.40M
Total Debt (Recent Filing)
$6.06M
Price to Earnings (P/E)
―
Beta
1.96
Next Earnings
Mar 10, 2027 (Est.)
EPS Estimate
-0.13
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Guidance

Double-digit quarterly growth and a raised full-year outlook indicate improving commercial execution across glaucoma and dry eye. If sustained, higher procedure adoption and recurring disposable usage can expand the revenue base and support operating leverage over the next several quarters.

Strong Product Economics

Very high gross margins provide meaningful contribution from each procedure and create a foundation for eventual profitability as revenue scales. Expense reductions and a sharply smaller loss also suggest management is improving cost discipline, although part of the margin gain was temporary.

Market Access And Product Expansion

Broader payer coverage lowers access barriers for OMNI and SION, while OMNI Ultra adds a cleared product that can support future adoption. Together, these developments strengthen the commercial platform and may expand the addressable procedure opportunity over multiple quarters.

Bears Say

Persistent Losses And Cash Burn

The company remains materially unprofitable and continues to consume cash, which limits internally funded growth and preserves dependence on its cash balance or future financing. Although quarterly usage improved, sustainable positive cash generation has not yet been achieved.

Litigation And Royalty Exposure

The confirmed judgment and ongoing royalty obligation could divert cash from product investment and reduce future economics on affected revenue. The appeal adds uncertainty, while the potential liability remains a durable financial and operational consideration rather than a temporary earnings fluctuation.

Dry Eye Reimbursement Uncertainty

TearCare adoption and procedure volumes depend partly on reimbursement decisions outside management's control. Delayed or narrower coverage could slow the dry-eye growth opportunity, reduce utilization at existing accounts, and make the recently raised revenue outlook more dependent on glaucoma performance.

Sight Sciences News

SGHT FAQ

What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.38 and its highest was $10.06 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $518.93M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s next earnings report is estimated for Mar 10, 2027 (not yet confirmed), which is in 125 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on Nov 04, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.003.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.13.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 55,087,990 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Sight Sciences?
Hedge funds hold Sight Sciences shares: the largest hedge-fund position in Sight Sciences is 71,886,545 shares, and hedge funds increased their holdings by 346.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology